Skip to main content
Top
Published in: Arthritis Research & Therapy 4/2010

Open Access 01-08-2010 | Research article

Modulation of collagen-induced arthritis by adenovirus-mediated intra-articular expression of modified collagen type II

Authors: Bo Tang, David L Cullins, Jing Zhou, Janice A Zawaski, Hyelee Park, David D Brand, Karen A Hasty, M Waleed Gaber, John M Stuart, Andrew H Kang, Linda K Myers

Published in: Arthritis Research & Therapy | Issue 4/2010

Login to get access

Abstract

Introduction

Rheumatoid arthritis (RA) is a systemic disease manifested by chronic inflammation in multiple articular joints, including the knees and small joints of the hands and feet. We have developed a unique modification to a clinically accepted method for delivering therapies directly to the synovium. Our therapy is based on our previous discovery of an analog peptide (A9) with amino acid substitutions made at positions 260 (I to A), 261 (A to B), and 263 (F to N) that could profoundly suppress immunity to type II collagen (CII) and arthritis in the collagen-induced arthritis model (CIA).

Methods

We engineered an adenoviral vector to contain the CB11 portion of recombinant type II collagen and used PCR to introduce point mutations at three sites within (CII124-402, 260A, 261B, 263D), (rCB11-A9) so that the resulting molecule contained the A9 sequence at the exact site of the wild-type sequence.

Results

We used this construct to target intra-articular tissues of mice and utilized the collagen-induced arthritis model to show that this treatment strategy provided a sustained, local therapy for individual arthritic joints, effective whether given to prevent arthritis or as a treatment. We also developed a novel system for in vivo bioimaging, using the firefly luciferase reporter gene to allow serial bioluminescence imaging to show that luciferase can be detected as late as 18 days post injection into the joint.

Conclusions

Our therapy is unique in that we target synovial cells to ultimately shut down T cell-mediated inflammation. Its effectiveness is based on its ability to transform potential inflammatory T cells and/or bystander T cells into therapeutic (regulatory-like) T cells which secrete interleukin (IL)-4. We believe this approach has potential to effectively suppress RA with minimal side effects.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kukar M, Petryna O, Efthimiou P: Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs. Biologics. 2009, 3: 443-457.PubMedCentralPubMed Kukar M, Petryna O, Efthimiou P: Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs. Biologics. 2009, 3: 443-457.PubMedCentralPubMed
2.
go back to reference Lakatos PL, Miheller P: Is there an increased risk of lymphoma and malignancies under anti-TNF therapy in IBD?. Curr Drug Targets. 2010, 11: 179-86. 10.2174/138945010790309867.CrossRefPubMed Lakatos PL, Miheller P: Is there an increased risk of lymphoma and malignancies under anti-TNF therapy in IBD?. Curr Drug Targets. 2010, 11: 179-86. 10.2174/138945010790309867.CrossRefPubMed
4.
go back to reference Mease PJ, Wei N, Fudman EJ, Kivitz AJ, Schechtman J, Trapp RG, Hobbs KF, Greenwald M, Hou A, Bookbinder SA, Graham GE, Wiesenhutter CW, Willis L, Ruderman EM, Forstot JZ, Maricic MJ, Dao KH, Pritchard CH, Fiske DN, Burch FX, Prupas HM, Anklesaria P, Heald AE: Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 Study. J Rheumatol. 2010, 37: 692-703. 10.3899/jrheum.090817.CrossRefPubMed Mease PJ, Wei N, Fudman EJ, Kivitz AJ, Schechtman J, Trapp RG, Hobbs KF, Greenwald M, Hou A, Bookbinder SA, Graham GE, Wiesenhutter CW, Willis L, Ruderman EM, Forstot JZ, Maricic MJ, Dao KH, Pritchard CH, Fiske DN, Burch FX, Prupas HM, Anklesaria P, Heald AE: Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 Study. J Rheumatol. 2010, 37: 692-703. 10.3899/jrheum.090817.CrossRefPubMed
5.
go back to reference Rabinovich GA, Daly G, Dreja H, Tailor H, Riera CM, Hirabayashi J, Chernajovsky Y: Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis. J Exp Med. 1999, 190: 385-398. 10.1084/jem.190.3.385.PubMedCentralCrossRefPubMed Rabinovich GA, Daly G, Dreja H, Tailor H, Riera CM, Hirabayashi J, Chernajovsky Y: Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis. J Exp Med. 1999, 190: 385-398. 10.1084/jem.190.3.385.PubMedCentralCrossRefPubMed
6.
go back to reference Chan JM, Villarreal G, Jin WW, Stepan T, Burstein H, Wahl SM: Intraarticular gene transfer of TNFR:Fc suppresses experimental arthritis with reduced systemic distribution of the gene product. Mol Ther. 2002, 6: 727-736. 10.1006/mthe.2002.0808.CrossRefPubMed Chan JM, Villarreal G, Jin WW, Stepan T, Burstein H, Wahl SM: Intraarticular gene transfer of TNFR:Fc suppresses experimental arthritis with reduced systemic distribution of the gene product. Mol Ther. 2002, 6: 727-736. 10.1006/mthe.2002.0808.CrossRefPubMed
7.
go back to reference Khoury M, Courties G, Fabre S, Bouffi C, Seemayer CA, Vervoordeldonk MJ, Tak PP, Jorgensen C, Apparailly F: Adeno-associated virus type 5-mediated intraarticular administration of tumor necrosis factor small interfering RNA improves collagen-induced arthritis. Arthritis Rheum. 2010, 62: 765-770. 10.1002/art.27302.CrossRefPubMed Khoury M, Courties G, Fabre S, Bouffi C, Seemayer CA, Vervoordeldonk MJ, Tak PP, Jorgensen C, Apparailly F: Adeno-associated virus type 5-mediated intraarticular administration of tumor necrosis factor small interfering RNA improves collagen-induced arthritis. Arthritis Rheum. 2010, 62: 765-770. 10.1002/art.27302.CrossRefPubMed
8.
go back to reference Myers LK, Tang B, Rosioniec EF, Stuart JM, Kang AH: An altered peptide ligand of type II collagen suppresses autoimmune arthritis. Crit Rev Immunol. 2007, 27: 345-356.CrossRefPubMed Myers LK, Tang B, Rosioniec EF, Stuart JM, Kang AH: An altered peptide ligand of type II collagen suppresses autoimmune arthritis. Crit Rev Immunol. 2007, 27: 345-356.CrossRefPubMed
9.
go back to reference Stuart JM, Cremer MA, Dixit SN, Kang AH, Townes AS: Collagen-induced arthritis in rats. Comparison of vitreous and cartilage-derived collagens. Arthritis Rheum. 1979, 22: 347-352. 10.1002/art.1780220406.CrossRefPubMed Stuart JM, Cremer MA, Dixit SN, Kang AH, Townes AS: Collagen-induced arthritis in rats. Comparison of vitreous and cartilage-derived collagens. Arthritis Rheum. 1979, 22: 347-352. 10.1002/art.1780220406.CrossRefPubMed
10.
go back to reference Rosloniec EF, Kang AH, Myers LK, Cremer MA: Collagen-induced arthritis. Current Protocols in Immunology. Edited by: Coico R, Shevach E. 2010, New York, NY: Wiley & Sons, 15.5.1-15.5.25. Rosloniec EF, Kang AH, Myers LK, Cremer MA: Collagen-induced arthritis. Current Protocols in Immunology. Edited by: Coico R, Shevach E. 2010, New York, NY: Wiley & Sons, 15.5.1-15.5.25.
11.
go back to reference Kingston RE, Chen CA, Rose JK: Calcium phosphate transfection. Curr Protoc Mol Biol. 2003, Chapter 9: Unit 9.1-PubMed Kingston RE, Chen CA, Rose JK: Calcium phosphate transfection. Curr Protoc Mol Biol. 2003, Chapter 9: Unit 9.1-PubMed
12.
go back to reference Lu Y, Zhang Y, Steiner MS: Efficient identification of recombinant adenoviruses by direct plaque screening. DNA Cell Biol. 1998, 17: 643-645. 10.1089/dna.1998.17.643.CrossRefPubMed Lu Y, Zhang Y, Steiner MS: Efficient identification of recombinant adenoviruses by direct plaque screening. DNA Cell Biol. 1998, 17: 643-645. 10.1089/dna.1998.17.643.CrossRefPubMed
13.
go back to reference Nokelainen M, Helaakoski T, Myllyharju J, Notbohm H, Pihlajaniemi T, Fietzek PP, Kivirikko KI: Expression and characterization of recombinant human type II collagens with low and high contents of hydroxylysine and its glycosylated forms. Matrix Biol. 1998, 16: 329-338. 10.1016/S0945-053X(98)90004-X.CrossRefPubMed Nokelainen M, Helaakoski T, Myllyharju J, Notbohm H, Pihlajaniemi T, Fietzek PP, Kivirikko KI: Expression and characterization of recombinant human type II collagens with low and high contents of hydroxylysine and its glycosylated forms. Matrix Biol. 1998, 16: 329-338. 10.1016/S0945-053X(98)90004-X.CrossRefPubMed
14.
go back to reference Myers LK, Tang B, Rosloniec EF, Stuart JM, Chiang TM, Kang AH: Characterization of a peptide analog of a determinant of type II collagen that suppresses collagen-induced arthritis. J Immunol. 1998, 161: 3589-3595.PubMed Myers LK, Tang B, Rosloniec EF, Stuart JM, Chiang TM, Kang AH: Characterization of a peptide analog of a determinant of type II collagen that suppresses collagen-induced arthritis. J Immunol. 1998, 161: 3589-3595.PubMed
15.
go back to reference Latham KA, Whittington KB, Zhou R, Qian Z, Rosloniec EF: Ex vivo characterization of the autoimmune T cell response in the HLA-DR1 mouse model of collagen-induced arthritis reveals long-term activation of type II collagen-specific cells and their presence in arthritic joints. J Immunol. 2005, 174: 3978-3985.CrossRefPubMed Latham KA, Whittington KB, Zhou R, Qian Z, Rosloniec EF: Ex vivo characterization of the autoimmune T cell response in the HLA-DR1 mouse model of collagen-induced arthritis reveals long-term activation of type II collagen-specific cells and their presence in arthritic joints. J Immunol. 2005, 174: 3978-3985.CrossRefPubMed
16.
go back to reference Myers LK, Tang B, Stuart JM, Kang AH: The role of IL-4 in regulation of murine collagen-induced arthritis. Clin Immunol. 2002, 102: 185-191. 10.1006/clim.2001.5162.CrossRefPubMed Myers LK, Tang B, Stuart JM, Kang AH: The role of IL-4 in regulation of murine collagen-induced arthritis. Clin Immunol. 2002, 102: 185-191. 10.1006/clim.2001.5162.CrossRefPubMed
17.
go back to reference Leung PS, Shu SA, Kenny TP, Wu PY, Tao MH: Development and validation of gene therapies in autoimmune diseases: Epidemiology to animal models. Autoimmun Rev. 2010, 9: A400-405. 10.1016/j.autrev.2009.12.009.CrossRefPubMed Leung PS, Shu SA, Kenny TP, Wu PY, Tao MH: Development and validation of gene therapies in autoimmune diseases: Epidemiology to animal models. Autoimmun Rev. 2010, 9: A400-405. 10.1016/j.autrev.2009.12.009.CrossRefPubMed
18.
go back to reference Evans CH, Robbins PD, Ghivizzani SC, Herndon JH, Kang R, Bahnson AB, Barranger JA, Elders EM, Gay S, Tomaino MM, Wasko MC, Watkins SC, Whiteside TL, Glorioso JC, Lotze MT, Wright TM: Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther. 1996, 7: 1261-1280. 10.1089/hum.1996.7.10-1261.CrossRefPubMed Evans CH, Robbins PD, Ghivizzani SC, Herndon JH, Kang R, Bahnson AB, Barranger JA, Elders EM, Gay S, Tomaino MM, Wasko MC, Watkins SC, Whiteside TL, Glorioso JC, Lotze MT, Wright TM: Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther. 1996, 7: 1261-1280. 10.1089/hum.1996.7.10-1261.CrossRefPubMed
19.
go back to reference Wehling P, Reinecke J, Baltzer AA, Granrath M, Schulitz KP, Schultz C, Krauspe R, Whiteside T, Elder E, Ghivizzani SC, Robbins PD, Evans CH: Clinical responses to gene therapy in joints of two subjects with rheumatoid arthritis. Hum Gene Ther. 2009, 20: 97-101. 10.1089/hum.2008.075.PubMedCentralCrossRefPubMed Wehling P, Reinecke J, Baltzer AA, Granrath M, Schulitz KP, Schultz C, Krauspe R, Whiteside T, Elder E, Ghivizzani SC, Robbins PD, Evans CH: Clinical responses to gene therapy in joints of two subjects with rheumatoid arthritis. Hum Gene Ther. 2009, 20: 97-101. 10.1089/hum.2008.075.PubMedCentralCrossRefPubMed
20.
go back to reference Takayanagi H, Juji T, Miyazaki T, Iizuka H, Takahashi T, Isshiki M, Okada M, Tanaka Y, Koshihara Y, Oda H, Kurokawa T, Nakamura K, Tanaka S: Suppression of arthritic bone destruction by adenovirus-mediated csk gene transfer to synoviocytes and osteoclasts. J Clin Invest. 1999, 104: 137-146. 10.1172/JCI6093.PubMedCentralCrossRefPubMed Takayanagi H, Juji T, Miyazaki T, Iizuka H, Takahashi T, Isshiki M, Okada M, Tanaka Y, Koshihara Y, Oda H, Kurokawa T, Nakamura K, Tanaka S: Suppression of arthritic bone destruction by adenovirus-mediated csk gene transfer to synoviocytes and osteoclasts. J Clin Invest. 1999, 104: 137-146. 10.1172/JCI6093.PubMedCentralCrossRefPubMed
21.
go back to reference Zhang H, Yang Y, Horton JL, Samoilova EB, Judge TA, Turka LA, Wilson JM, Chen Y: Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. J Clin Invest. 1997, 100: 1951-1957. 10.1172/JCI119726.PubMedCentralCrossRefPubMed Zhang H, Yang Y, Horton JL, Samoilova EB, Judge TA, Turka LA, Wilson JM, Chen Y: Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. J Clin Invest. 1997, 100: 1951-1957. 10.1172/JCI119726.PubMedCentralCrossRefPubMed
22.
go back to reference Ghivizzani SC, Lechman ER, Tio C, Mule KM, Chada S, McCormack JE, Evans CH, Robbins PD: Direct retrovirus-mediated gene transfer to the synovium of the rabbit knee: implications for arthritis gene therapy. Gene Ther. 1997, 4: 977-982. 10.1038/sj.gt.3300486.CrossRefPubMed Ghivizzani SC, Lechman ER, Tio C, Mule KM, Chada S, McCormack JE, Evans CH, Robbins PD: Direct retrovirus-mediated gene transfer to the synovium of the rabbit knee: implications for arthritis gene therapy. Gene Ther. 1997, 4: 977-982. 10.1038/sj.gt.3300486.CrossRefPubMed
24.
go back to reference Backlund J, Carlsen S, Hoger T, Holm B, Fugger L, Kihlberg J, Burkhardt H, Holmdahl R: Predominant selection of T cells specific for the glycosylated collagen type II epitope (263-270) in humanized transgenic mice and in rheumatoid arthritis. Proc Natl Acad Sci USA. 2002, 99: 9960-9965. 10.1073/pnas.132254199.PubMedCentralCrossRefPubMed Backlund J, Carlsen S, Hoger T, Holm B, Fugger L, Kihlberg J, Burkhardt H, Holmdahl R: Predominant selection of T cells specific for the glycosylated collagen type II epitope (263-270) in humanized transgenic mice and in rheumatoid arthritis. Proc Natl Acad Sci USA. 2002, 99: 9960-9965. 10.1073/pnas.132254199.PubMedCentralCrossRefPubMed
25.
go back to reference Corthay A, Backlund J, Holmdahl R: Role of glycopeptide-specific T cells in collagen-induced arthritis: an example how post-translational modification of proteins may be involved in autoimmune disease. Ann Med. 2001, 33: 456-465. 10.3109/07853890109002094.CrossRefPubMed Corthay A, Backlund J, Holmdahl R: Role of glycopeptide-specific T cells in collagen-induced arthritis: an example how post-translational modification of proteins may be involved in autoimmune disease. Ann Med. 2001, 33: 456-465. 10.3109/07853890109002094.CrossRefPubMed
26.
go back to reference Michaelsson E, Malmstrom V, Reis S, Engstrom A, Burkhardt H, Holmdahl R: T cell recognition of carbohydrates on type II collagen. J Exp Med. 1994, 180: 745-749. 10.1084/jem.180.2.745.CrossRefPubMed Michaelsson E, Malmstrom V, Reis S, Engstrom A, Burkhardt H, Holmdahl R: T cell recognition of carbohydrates on type II collagen. J Exp Med. 1994, 180: 745-749. 10.1084/jem.180.2.745.CrossRefPubMed
27.
go back to reference Dzhambazov B, Nandakumar KS, Kihlberg J, Fugger L, Holmdahl R, Vestberg M: Therapeutic vaccination of active arthritis with a glycosylated collagen type II peptide in complex with MHC class II molecules. J Immunol. 2006, 176: 1525-1533.CrossRefPubMed Dzhambazov B, Nandakumar KS, Kihlberg J, Fugger L, Holmdahl R, Vestberg M: Therapeutic vaccination of active arthritis with a glycosylated collagen type II peptide in complex with MHC class II molecules. J Immunol. 2006, 176: 1525-1533.CrossRefPubMed
28.
go back to reference Myers LK, Sakurai Y, Rosloniec EF, Stuart JM, Kang AH: An analog peptide that suppresses collagen-induced arthritis. Am J Med Sci. 2004, 327: 212-216. 10.1097/00000441-200404000-00007.CrossRefPubMed Myers LK, Sakurai Y, Rosloniec EF, Stuart JM, Kang AH: An analog peptide that suppresses collagen-induced arthritis. Am J Med Sci. 2004, 327: 212-216. 10.1097/00000441-200404000-00007.CrossRefPubMed
Metadata
Title
Modulation of collagen-induced arthritis by adenovirus-mediated intra-articular expression of modified collagen type II
Authors
Bo Tang
David L Cullins
Jing Zhou
Janice A Zawaski
Hyelee Park
David D Brand
Karen A Hasty
M Waleed Gaber
John M Stuart
Andrew H Kang
Linda K Myers
Publication date
01-08-2010
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 4/2010
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3074

Other articles of this Issue 4/2010

Arthritis Research & Therapy 4/2010 Go to the issue